Navigation Links
Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies
Date:11/9/2009

uated participants' signs and symptoms of ADHD on a once-weekly basis using the clinician administered and scored ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials that assesses hyperactive, impulsive, and inattentive symptoms. The primary outcome was the change in total ADHD-RS-IV scores from baseline to end point in both studies.

Both trials demonstrated statistically significant improvements in ADHD-RS-IV scores in patients taking INTUNIV beginning one to two weeks after patients began receiving once-daily doses of INTUNIV. In the first pivotal trial, the mean reduction in ADHD-RS-IV total scores at end point were -16.7 for INTUNIV compared to -8.9 for placebo (P< .0001); the mean reduction in ADHD-RS-IV total scores in the second pivotal trial were -19.6 for INTUNIV and -12.2 for placebo (P=.0040). Placebo-adjusted LS mean changes from baseline were statistically significant for all INTUNIV doses in the randomized treatment groups in both studies.

Additional secondary efficacy outcome measures included the Conners' Parent Rating Scale-Revised: Short Form (CPRS-R) and the Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R). CPRS-R and CTRS-R are comprehensive scales that use parent and teacher observer and self-report ratings to help assess ADHD symptoms and behaviors in children and adolescents. Among some of the symptoms measured were: inattentiveness/being easily distracted, running around or climbing excessively, arguing with adults, losing temper, and interrupting or intruding on others. Significant improvements in mean day total scores were seen on both scales: based on the CPRS-R, parents reported significant improvement across a full day (as measured at 6 PM, 8 PM, and 6 AM the next morning); based on the CTRS-R, which was used only in the first pivotal trial, teachers reported significant improvement throughout the school day (as measured at 10 AM and 2 PM).

Safety was also
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
2. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
3. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
4. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
5. Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
8. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
9. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
10. Once-Daily Combo Works for New HIV Patients
11. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Mutare Health, a ... nationally-renowned Gastroenterologist Lawrence Kosinski, MD, MBA, AGAF, to ... Kosinski brings a unique combination of medical experience, ... Mutare Health team as it continues ... and quality of care in the healthcare environment. ...
(Date:4/20/2015)... 20, 2015 Novatus, a leading ... expanded its service level to the growing European ... Amsterdam and Paris. After a rigorous review ... levels of resilience, security and operational expertise, and ... for Novatus as we expand our footprint and ...
(Date:4/20/2015)... York (PRWEB) April 20, 2015 ... representing the U.S. health insurance industry, is seeking ... of the recent controversy involving surgical tools called ... to U.S. Senator Robert Casey (D-PA) dated April ... surrounding uterine morcellation point to “serious gaps in ...
(Date:4/20/2015)... 1% for the Planet , one of ... Kate Williams, the network’s Director of Partnerships, will step into ... has been part of 1% for the Planet since early ... the Northern Forest Canoe Trail, a 1% for the Planet ... stewardship of and advocacy for the outdoors, a commitment which ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 in ... The group was more than just about rock music. They ... rock, country, and other genres to put together their greatest ... group was inducted into the Rock and Roll Hall of ... 35 million records worldwide. This year marks the 50th ...
Breaking Medicine News(10 mins):Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 2Health News:Dr. Lawrence Kosinski Merges Medical, Technical, Business Expertise as CMO for Mutare Health 3Health News:Novatus Expands into European Data Centers 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2
... an AIDS drug and a heart medicine, and entered into ... more people can be treated. ,The negotiation panel ... first talks with US firm Abbott to discuss a price ... head of the department of disease control, said the firm ...
... the light-sensitive protein found in many marine bacteria. ... National Laboratory (Berkeley Lab) and the University of California ... respire oxygen is impaired, bacterium equipped with proteorhodopsin will ... processes. ,“Our research shows that proteorhodopsin ...
... accurately identify colorectal cancer patients with a specific type ... patient has an inherited// form of the disease or ... ,Some people with colorectal cancer have defects in ... these mutations by looking for a gene marker called ...
... solved a decades-old cancer mystery. "We not only found ... master switch for a tumor suppressive network that means ... said CSHL Associate Professor Alea Mills, Ph.D. The study, ... of Cell. ,Specifically, Mills' discovery identifies CHD5, ...
... cases of malaria due to Plasmodium falciparum on the island ... reported cases, 264 have occurred in Kingston// , 12 in ... There have been no reported deaths due to malaria. ... the WHO Regional Office for the Americas coordinated by the ...
... IV study of KADIAN ? (morphine sulfate extended-release) Capsules ... leading pharmaceutical company. It reveals that the pharmacokinetics// of ... consumption of alcohol. ,Results of this pharmacokinetic ... by the U.S. Food and Drug Administration (FDA) to ...
Cached Medicine News:Health News:Thailand Backs Off Threat to Break Drug Patents 2Health News:Shedding New Light on Proteorhodopsin 2Health News:Scientists Discover New Gene 2Health News:KADIAN Efficacy Not Affected by Alcohol Consumption 2
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... Mass. , April 20, 2015 ... and final clinical results for the Phase 1 ... in HER2-positive metastatic breast cancer.  The results were ... clinical trials plenary oral session at the 2015 ... in Philadelphia, PA. Data ...
(Date:4/20/2015)... YORK , April 20, 2015 This report ... Instruments in US$ Million by the following Product Segments: Sphygmomanometers ... and Blood Pressure Transducers. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates and forecasts ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5World Blood Pressure Monitoring and Measurement Instruments Industry 2World Blood Pressure Monitoring and Measurement Instruments Industry 3World Blood Pressure Monitoring and Measurement Instruments Industry 4World Blood Pressure Monitoring and Measurement Instruments Industry 5World Blood Pressure Monitoring and Measurement Instruments Industry 6World Blood Pressure Monitoring and Measurement Instruments Industry 7World Blood Pressure Monitoring and Measurement Instruments Industry 8World Blood Pressure Monitoring and Measurement Instruments Industry 9World Blood Pressure Monitoring and Measurement Instruments Industry 10World Blood Pressure Monitoring and Measurement Instruments Industry 11World Blood Pressure Monitoring and Measurement Instruments Industry 12World Blood Pressure Monitoring and Measurement Instruments Industry 13World Blood Pressure Monitoring and Measurement Instruments Industry 14World Blood Pressure Monitoring and Measurement Instruments Industry 15World Blood Pressure Monitoring and Measurement Instruments Industry 16World Blood Pressure Monitoring and Measurement Instruments Industry 17World Blood Pressure Monitoring and Measurement Instruments Industry 18World Blood Pressure Monitoring and Measurement Instruments Industry 19World Blood Pressure Monitoring and Measurement Instruments Industry 20World Blood Pressure Monitoring and Measurement Instruments Industry 21World Blood Pressure Monitoring and Measurement Instruments Industry 22World Blood Pressure Monitoring and Measurement Instruments Industry 23World Blood Pressure Monitoring and Measurement Instruments Industry 24World Blood Pressure Monitoring and Measurement Instruments Industry 25World Blood Pressure Monitoring and Measurement Instruments Industry 26World Blood Pressure Monitoring and Measurement Instruments Industry 27World Blood Pressure Monitoring and Measurement Instruments Industry 28
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: